#USA #Houston #exosome technology #PranaX #Phillip Maderia

PranaX Corporation's New Leadership

PranaX Corporation, renowned for its groundbreaking work in exosome-based regenerative wellness, has announced the recent appointment of Phillip Maderia as Chief Executive Officer. This strategic move is set to bolster the company's mission of harnessing exosomes—nature’s cellular messengers—to improve the quality of life for individuals by offering innovative wellness products.

Phillip Maderia brings over 30 years of extensive experience in the biopharmaceutical manufacturing sector, particularly in exosome production. This expertise is expected to catalyze PranaX's efforts to develop exosomes into safe, physician-directed wellness supplements that can significantly enhance health care solutions on a global scale.

Previously, Maderia served as the Site Head and exosome Business Leader at Lonza’s Lexington facility. At Lonza, he successfully managed the business expansion of their exosome division, which operated on a budget of $12 million. His most notable achievement was overseeing the construction of a pioneering 500-liter scale Good Manufacturing Practice (GMP) exosome production process. Maderia’s unwavering commitment to advancing exosome technology also played a crucial role in Lonza's acquisition of Codiak BioSciences' intellectual property in 2023, positioning Lonza as a leader in the exosome field.

Prior to his role at Lonza, he made significant contributions at Codiak BioSciences, where he was instrumental in supplying exosome clinical programs focused on oncology. He has held senior leadership positions in manufacturing and engineering at LFB-USA and Sanofi Genzyme, contributing greatly to the biologics manufacturing sector.

Steven J. Greco, PhD and Founder of PranaX, commented on Maderia’s selection, stating, “Phillip’s exceptional track record in exosome and biologics manufacturing and his unique ability to translate complex scientific principles into practical solutions make him the ideal leader to drive PranaX forward. His arrival marks an essential phase in our journey to develop exosome-based products that can benefit countless lives.”

Maderia himself expressed enthusiasm regarding his new role: “I am thrilled to lead PranaX at this pivotal time. The potential of exosomes in regenerative wellness is immense, and I resonate deeply with the company's goal to make these advantages widely accessible. I am eager to work with our team to deliver natural, scientifically-supported products geared towards empowering individuals to lead healthier and more vibrant lives.”

As new CEO, Maderia aims to expedite research and development within PranaX, fostering strategic partnerships and rolling out innovative exosome-centered solutions in the wellness market. These initiatives underline PranaX’s commitment to solidifying its status as a global frontrunner in next-generation health.

Established with the mission of unlocking the regenerative properties inherent in stem cell-derived exosomes, PranaX is dedicated to rejuvenating aging, inflamed, and damaged tissues through evidence-based approaches. Positioned at the forefront of regenerative medicine, the company is headquartered at the Levit Green life sciences campus in Houston, Texas, where it conducts its research, development, and manufacturing operations.

In conclusion, Phillip Maderia's leadership is anticipated to herald a new chapter for PranaX, intensifying its impact on health and wellness through innovative exosome technologies. As the world increasingly acknowledges the significance of regenerative health, PranaX is poised to lead the charge toward a healthier future for all.